The US Food and Drug Administration (FDA) has approved a label expansion for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, into biliary tract cancer (BTC).

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed ...

According to Roche, the HER2 (4B5) clone consistently achieves high proficiency assessment scores against other clones. "FDA ...

which indicates that lapatinib exerts its main effects via the HER2 pathway. Around 1.3 million women are diagnosed with breast cancer annually worldwide, which represents 23% of all cancers in women.

The addition of trastuzumab to adjuvant chemotherapy for women with HER2-positive breast cancer is potentially associated with an increased risk of cardiac dysfunction (CD), specifically when the ...

Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...

Rabbit Monoclonal Primary Antibody test as a companion diagnostic to assess HER2+ status in patients with BTC.